File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma

TitleA hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma
Authors
KeywordsChemoresistance
Cisplatin
HCC
Hemoglobin-based oxygen carrier
Intravital imaging
Issue Date2017
PublisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html
Citation
Oncotarget, 2017, v. 8 n. 49, p. 85311-85325 How to Cite?
AbstractBackground and Objective: Our previous study showed that liver graft injury not only promotes tumor recurrence, but also induces chemoresistance in recurrent HCC after liver transplantation. Recently, we found that the hemoglobin-based oxygen carrier'YQ23' significantly ameliorates hepatic IR injury and prevent tumor recurrence. Here, we intended to explore the novel therapeutic strategy using oxygen carrier 'YQ23'to sensitize chemotherapy in HCC. Methods: To investigate the role of YQ23 combined with Cisplatin, the proliferation of HCC cells was examined under combined treatment by MTT and colony formation. To explore the effect of YQ23 on sensitization of Cisplatin based chemotherapy, the orthotopic liver cancer model was established. To characterize the delivery of YQ23 in tumor tissue, the intravital imaging system was applied for longitudinal observation in ectopic liver cancer model. The distribution of YQ23 was examined by IVIS spectrum. Results: YQ23 significantly suppressed the proliferation of HCC cells under Cisplatin treatment in a dose and time dependent manner. Moreover, YQ23 administration significantly sensitized Cisplatin based chemotherapy in orthotopic liver cancer model. Down-regulation of DHFR may be one of the reasons for YQ23 sensitizing Cisplatin based chemotherapy. Real-time intravital imaging showed that YQ23 accumulated in the tumor tissue and maintained as long as 3 days in ectopic liver cancer model. The IVIS spectrum examination showed that YQ23 distributed mainly at liver and bladder within the first 36 hours after administration in orthotopic liver cancer model. Conclusion: YQ23 treatment may be a potential therapeutic strategy to sensitize chemotherapy in HCC.
Persistent Identifierhttp://hdl.handle.net/10722/259547
ISSN
2015 Impact Factor: 5.008
2015 SCImago Journal Rankings: 2.294
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorQi, X-
dc.contributor.authorWong, BL-
dc.contributor.authorLau, SH-
dc.contributor.authorNg, KTP-
dc.contributor.authorKwok, SY-
dc.contributor.authorSun, KW-
dc.contributor.authorTzang, FC-
dc.contributor.authorShao, Y-
dc.contributor.authorLi, C-
dc.contributor.authorGeng, W-
dc.contributor.authorLing, C-
dc.contributor.authorMa, YY-
dc.contributor.authorLiu, X-
dc.contributor.authorLiu, H-
dc.contributor.authorLiu, J-
dc.contributor.authorYeung, WHO-
dc.contributor.authorLo, CM-
dc.contributor.authorMan, K-
dc.date.accessioned2018-09-03T04:09:43Z-
dc.date.available2018-09-03T04:09:43Z-
dc.date.issued2017-
dc.identifier.citationOncotarget, 2017, v. 8 n. 49, p. 85311-85325-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/10722/259547-
dc.description.abstractBackground and Objective: Our previous study showed that liver graft injury not only promotes tumor recurrence, but also induces chemoresistance in recurrent HCC after liver transplantation. Recently, we found that the hemoglobin-based oxygen carrier'YQ23' significantly ameliorates hepatic IR injury and prevent tumor recurrence. Here, we intended to explore the novel therapeutic strategy using oxygen carrier 'YQ23'to sensitize chemotherapy in HCC. Methods: To investigate the role of YQ23 combined with Cisplatin, the proliferation of HCC cells was examined under combined treatment by MTT and colony formation. To explore the effect of YQ23 on sensitization of Cisplatin based chemotherapy, the orthotopic liver cancer model was established. To characterize the delivery of YQ23 in tumor tissue, the intravital imaging system was applied for longitudinal observation in ectopic liver cancer model. The distribution of YQ23 was examined by IVIS spectrum. Results: YQ23 significantly suppressed the proliferation of HCC cells under Cisplatin treatment in a dose and time dependent manner. Moreover, YQ23 administration significantly sensitized Cisplatin based chemotherapy in orthotopic liver cancer model. Down-regulation of DHFR may be one of the reasons for YQ23 sensitizing Cisplatin based chemotherapy. Real-time intravital imaging showed that YQ23 accumulated in the tumor tissue and maintained as long as 3 days in ectopic liver cancer model. The IVIS spectrum examination showed that YQ23 distributed mainly at liver and bladder within the first 36 hours after administration in orthotopic liver cancer model. Conclusion: YQ23 treatment may be a potential therapeutic strategy to sensitize chemotherapy in HCC.-
dc.languageeng-
dc.publisherImpact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html-
dc.relation.ispartofOncotarget-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectChemoresistance-
dc.subjectCisplatin-
dc.subjectHCC-
dc.subjectHemoglobin-based oxygen carrier-
dc.subjectIntravital imaging-
dc.titleA hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma-
dc.typeArticle-
dc.identifier.emailNg, KTP: ledodes@hku.hk-
dc.identifier.emailMa, YY: yyma@HKUCC-COM.hku.hk-
dc.identifier.emailLiu, X: liuxb301@hku.hk-
dc.identifier.emailLiu, H: liuhui25@hku.hk-
dc.identifier.emailLiu, J: liujiang@hku.hk-
dc.identifier.emailYeung, WHO: why21@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.emailMan, K: kwanman@hku.hk-
dc.identifier.authorityNg, KTP=rp01720-
dc.identifier.authorityLo, CM=rp00412-
dc.identifier.authorityMan, K=rp00417-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.18632/oncotarget.19672-
dc.identifier.scopuseid_2-s2.0-85031496004-
dc.identifier.hkuros288729-
dc.identifier.volume8-
dc.identifier.issue49-
dc.identifier.spage85311-
dc.identifier.epage85325-
dc.identifier.isiWOS:000413077800066-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats